-
Mashup Score: 2
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 14SABCS24 ONCOALERT | ONCOBITES - 19 day(s) ago
In an interview, Dr. Agostinetto delves into the findings of Dr. Souza, who shares the results of his research explaining why larotrectinib is positioned as an effective and safe treatment option for patients with TRK fusion breast cancer. Dr. Cristiano de P á dua Souza MD, Jules Bordet Institute, Brussels,
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet-
Join our collaborators at @OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective tx for TRK fusion #BreastCancer straight out of #SABCS24 Link to view: https://t.co/SPBw9mdKdM Dr. @ElisaAgostinett Elisa Agostinetto from… https://t.co/eXuCQI7zW3 https://t.co/WWpR0j2VYF
-
-
Mashup Score: 10SABCS24 ONCOALERT | ONCOBITES - 25 day(s) ago
In an interview, Dr. Agostinetto delves into the findings of Dr. Souza, who shares the results of his research explaining why larotrectinib is positioned as an effective and safe treatment option for patients with TRK fusion breast cancer. Dr. Cristiano de P á dua Souza MD, Jules Bordet Institute, Brussels,
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet-
Join our collaborators at @OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective tx for TRK fusion #BreastCancer #SABCS24 Link to view: https://t.co/IHi0sALPjO Dr. @ElisaAgostinett Elisa Agostinetto from the Jules… https://t.co/6JvXP1Kh33 https://t.co/wmD1obxNaJ
-
-
Mashup Score: 17Komal Jhaveri, MD, FACP on The Phase III EMBER Trial - 1 month(s) ago
At the San Antonio Breast Cancer Symposium, Komal Jhaveri, MD, FACP, presented results of the phase III EMBER-3 trial of imlunestrant, an oral selective estrogen receptor degrader as monotherapy and combined with abemaciclib for patients with ER+/HER2-negative advanced breast cancer. Disclaimer: This video transcript has not been proofread or edited and may contain errors. Speaker 1: At the San Antonio Breast Cancer meeting this year, I had the opportunity to present the results from the Phase III
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
In this video @jhaveri_komal discusses the results of the phase III EMBER-3 trial of imlunestrant. She presented on this oral selective estrogen receptor degrader for #breastcancer treatment at #SABCS24. https://t.co/bi4u3qVMBb https://t.co/aw2CerKFRp
-
-
Mashup Score: 17
Alexis LeVee, MD, City of Hope, Duarte, CA, comments on the incidence and predictors of immune-related adverse events (irAE) in patients with early-stage breast cancer treated with immune checkpoint inhibitors. Findings from a cohort of patients reveal that a majority experienced irAE, which is higher than the reported rate in the KEYNOTE-522 trial (NCT03036488). Older age and comorbidities such as chronic kidney disease were also risk factors for severe irAE. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
Risk factors for immune-related adverse events in early-stage #BreastCancer Report with @AlexisLevee from @VJOncology at #SABCS24 LINK To Watch👉 https://t.co/jB5wV5F4uY A recent analysis of immune-related adverse events (irAEs) in patients with early-stage breast cancer… https://t.co/Z4DCQwVZnZ https://t.co/X5vaoC0Zte
-
-
Mashup Score: 0
No significant survival benefits were found when comparing three CDK4/6 inhibitor combinations with initial treatment for HR-positive, HER2-negative metastatic breast cancer.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
When comparing three CDK4/6 inhibitor combinations during the initial treatment for hormone receptor (HR)-positive, HER2-negative metastatic #BreastCancer, no significant overall survival advantage was found, as presented at #SABCS24. https://t.co/xyRTZdi19n
-
-
Mashup Score: 3Thousands of women with breast cancer may not need ANY treatment - 2 month(s) ago
A breast cancer diagnosis is almost always followed by invasive biopsies, surgery, radiotherapy, chemotherapy and hormone treatments. But could all that be set to change?
Source: www.dailymail.co.ukCategories: General Medicine News, Oncologists1Tweet-
Olaparib slashes the risk of death from #BreastCancer. Read about the results, presented at #SABCS24, from the OlympiA trial of olaparib for early breast cancer in @MailOnline ⤵️ https://t.co/lYrBplu7tR
-
-
Mashup Score: 3Thousands of women with breast cancer may not need ANY treatment - 2 month(s) ago
A breast cancer diagnosis is almost always followed by invasive biopsies, surgery, radiotherapy, chemotherapy and hormone treatments. But could all that be set to change?
Source: www.dailymail.co.ukCategories: General Medicine News, Oncologists1Tweet-
Olaparib slashes the risk of death from #BreastCancer. Read about the results, presented at #SABCS24, from the OlympiA trial of olaparib for early breast cancer in @MailOnline ⤵️ https://t.co/lYrBplu7tR
-
-
Mashup Score: 1
A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, HER2-negative breast cancer.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Patients with germline BRCA-mutated estrogen receptor-positive, HER2-negative #BreastCancer demonstrated responses after receiving a combination of neoadjuvant Zejula plus Jemperli, as presented at #SABCS24. https://t.co/FVkgOrE6v1
-
-
Mashup Score: 0Tecentriq Regimen Misses End Goal in Triple-Negative Breast Cancer - 2 month(s) ago
Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of complete tumor removal.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
For patients with triple-negative #BreastCancer, Tecentriq plus neoadjuvant chemotherapy followed by adjuvant Tecentriq did not significantly improve event-free survival, missing the primary end point of a phase 3 N trial, presented at #SABCS24. https://t.co/InAFwcCZRM
-
Adjuvant tamoxifen significantly reduces the risk of recurrence in #breastcancer patients with "good-risk" ductal carcinoma in situ who forgo radiation therapy after breast-conserving surgery, according to a study presented at #SABCS24. https://t.co/N7YchpJfeG https://t.co/RoGLsrDNz0